What is Alkermes's LUMRYZ — revenue?

Alkermes (ALKS) reported LUMRYZ — revenue of $39.49M in Q1 2026.

What does LUMRYZ — revenue mean?

The total net sales generated by the LUMRYZ product line after accounting for returns and excluding sales taxes.

How do you interpret LUMRYZ — revenue?

An increase indicates growing market adoption, successful commercial execution, or expanded patient access for the therapy. A decrease may signal increased competition, loss of patent exclusivity, or challenges in market reimbursement.

How does LUMRYZ — revenue compare across companies?

Comparable to product-specific net revenue line items reported by other biopharmaceutical companies, often benchmarked against therapeutic area peers or similar specialty pharmacy products.

Alkermes ALKS LUMRYZ — Revenue

Other product segments

Vivitrol

$112.43M—

Aristada And Aristada Initio

$93.82M—

LYBALVI

$92.36M—

Similar metrics at other companies

JAZZLumryz Product For Non-Narcolepsy Indications — Royalty rate for sales to be received

10%—

JAZZLumryz Product For Narcolepsy Indications — Royalty rate for sales to be received

3.9%—

JAZZRylaze/Enrylaze — Revenue from Contract with Customer, Excluding Assessed Tax

$103.7M+10.1%

JAZZLumryz Product For Non-Narcolepsy Indications, Unpermitted Net Sales — Royalty rate for sales to be received

20%—

LUMNBusiness — Revenue (Gross)

$3.96B—

LUMNCorporate Non — Revenue

$183M+6.4%

Other financials

Income statement

See full

Revenue$392.9M+28.2%

Gross profit$331.3M+28.8%

Operating income-$48.3M-450%

Net income-$66.5M-396%

EPS (diluted)-$0.40-408%

Balance sheet

See full

Cash & equivalents$351.6M-12.1%

Total debt$1.6B+2,034%

Total equity$1.8B+15.9%

Total assets$4.3B+105%

Cash flow

See full

Operating cash flow-$165.7M-268%

CapEx$4.1M-59.5%

Free cash flow-$169.8M-291%

Valuation

See full

Market cap$7.5B+9.7%

Enterprise value$8.73B+41.2%

P/E49.1×+29.7×

P/S4.8×+0.3×

Profitability

See full

Gross margin86.6%+2.2pp

Operating margin12.3%-13.6pp

Net margin9.8%-13.5pp

FCF margin14.2%-17.6pp

Returns & leverage

See full

Return on equity9.4%-16.1pp

Debt / equity0.9×+0.9×

Current ratio2.3×-1.1×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's lumryz — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alkermes's LUMRYZ — revenue?: Alkermes (ALKS) reported LUMRYZ — revenue of $39.49M in Q1 2026.
What does LUMRYZ — revenue mean?: The total net sales generated by the LUMRYZ product line after accounting for returns and excluding sales taxes.
How do you interpret LUMRYZ — revenue?: An increase indicates growing market adoption, successful commercial execution, or expanded patient access for the therapy. A decrease may signal increased competition, loss of patent exclusivity, or challenges in market reimbursement.
How does LUMRYZ — revenue compare across companies?: Comparable to product-specific net revenue line items reported by other biopharmaceutical companies, often benchmarked against therapeutic area peers or similar specialty pharmacy products.